- Home
- MIRM vs RBA Comparison
MIRM vs RBA Comparison
Compare MIRM & RBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- RBA
- Stock Information
- Founded
- MIRM 2018
- RBA 1958
- Country
- MIRM United States
- RBA United States
- Employees
- MIRM N/A
- RBA N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- RBA Business Services
- Sector
- MIRM Health Care
- RBA Consumer Discretionary
- Exchange
- MIRM Nasdaq
- RBA Nasdaq
- Market Cap
- MIRM 1.9B
- RBA 18.1B
- IPO Year
- MIRM 2019
- RBA 1998
- Fundamental
- Price
- MIRM $39.10
- RBA $97.38
- Analyst Decision
- MIRM Strong Buy
- RBA Buy
- Analyst Count
- MIRM 11
- RBA 7
- Target Price
- MIRM $58.55
- RBA $107.50
- AVG Volume (30 Days)
- MIRM 476.2K
- RBA 1.1M
- Earning Date
- MIRM 05-07-2025
- RBA 05-07-2025
- Dividend Yield
- MIRM N/A
- RBA 1.19%
- EPS Growth
- MIRM N/A
- RBA 93.27
- EPS
- MIRM N/A
- RBA 2.01
- Revenue
- MIRM $336,888,000.00
- RBA $4,284,200,000.00
- Revenue This Year
- MIRM $29.51
- RBA $3.31
- Revenue Next Year
- MIRM $20.27
- RBA $4.74
- P/E Ratio
- MIRM N/A
- RBA $48.45
- Revenue Growth
- MIRM 80.76
- RBA 16.43
- 52 Week Low
- MIRM $23.14
- RBA $69.83
- 52 Week High
- MIRM $54.23
- RBA $106.90
- Technical
- Relative Strength Index (RSI)
- MIRM 34.64
- RBA 50.80
- Support Level
- MIRM $37.83
- RBA $95.47
- Resistance Level
- MIRM $40.32
- RBA $98.58
- Average True Range (ATR)
- MIRM 2.47
- RBA 3.47
- MACD
- MIRM -0.33
- RBA 0.12
- Stochastic Oscillator
- MIRM 25.14
- RBA 70.97
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About RBA RB Global Inc.
RB Global operates the world's largest auction for heavy equipment. The company started as a live auctioneer of industrial equipment; since then it has greatly expanded its operations to include the sale of construction, agricultural, oilfield, and transportation equipment. RB Global operates over 40 live auction sites in more than 12 countries, along with online marketplaces, including IronPlanet, Marketplace-E, and GovPlanet. Its agricultural auctions are frequently much smaller venues and can include liquidations of single farms. The company holds over 300 auctions yearly and sells $6 billion worth of equipment.